Gold prices steady above $3,400/oz on rate cut bets; PCE data awaited
Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.28 billion market cap biotech company with strong financial health metrics according to InvestingPro, sold shares of the company’s common stock on July 7, 2025, for a total value of $131950.
The sales involved two transactions. In the first, 6,362 shares were sold at a weighted average price of $19.7483, with individual prices ranging from $19.46 to $20.175. The second transaction involved the sale of 305 shares at a weighted average price of $20.6948, with prices ranging from $20.58 to $20.82. The stock currently trades at $21.54, showing recent momentum with a 4.55% gain over the past week.
Following these transactions, Patel continues to indirectly own 296,642 shares of Enliven Therapeutics through The Patel / Dong Family Trust.
These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.
In other recent news, Enliven Therapeutics announced the pricing of a $200 million public offering, which includes common stock shares and pre-funded warrants. The company expects to raise approximately $200 million in gross proceeds from this transaction, with the offering anticipated to close around June 16, 2025. H.C. Wainwright has raised its price target for Enliven Therapeutics to $48 from $40, maintaining a Buy rating, following positive data from the Phase 1a/1b ENABLE trial for ELVN-001. Additionally, TD Cowen reiterated its Buy rating on Enliven Therapeutics, highlighting the strong market potential for ELVN-001, which could reach peak sales of $3 billion if approved. Goldman Sachs also initiated coverage with a Buy rating and a $37 price target, noting the promising Phase 1 data for ELVN-001. The drug candidate has shown a 47% major molecular response rate by 24 weeks, with a favorable safety profile, and is projected to enter pivotal clinical development in 2026. Enliven plans to initiate a Phase 3 trial in 2026, with analysts projecting significant competitive positioning against existing treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.